Associations of Patient Mood, Modulators of Quality of Life, and Pharmaceuticals with Amyotrophic Lateral Sclerosis Survival Duration
Open Access
- 10 January 2020
- journal article
- research article
- Published by MDPI AG in Behavioral Sciences
- Vol. 10 (1) , 33
Abstract
Associations of modulators of quality of life (QoL) and survival duration are assessed in the fatal motor neuron disease, Amyotrophic Lateral Sclerosis. Major categories include clinical impression of mood (CIM); physical health; patient social support; and usage of interventions, pharmaceuticals, and supplements. Associations were assessed at p < 0.05 and p < 0.001 significance thresholds using applicable methods (Chi-square, t-test, ANOVA, logistical regression, random forests, Fisher’s exact test) within a retrospective cohort of 1585 patients. Factors significantly correlated with positive (happy or normal) mood included family support and usage of bi-level positive airway pressure (Bi-PAP) and/or cough assist. Decline in physical factors like presence of dysphagia, drooling, general pain, and decrease in ALSFRS-R total score or forced vital capacity (FVC) significantly correlated with negative (depressed or anxious) mood (p < 0.05). Use of antidepressants or pain medications had no association with ALS patient mood (p > 0.05), but were significantly associated with increased survival (p < 0.05). Positive patient mood, Bi-PAP, cough assist, percutaneous endoscopic gastrostomy (PEG), and accompaniment to clinic visits associated with increased survival duration (p < 0.001). Of the 47 most prevalent pharmaceutical and supplement categories, 17 associated with significant survival duration increases ranging +4.5 to +16.5 months. Tricyclic antidepressants, non-opioids, muscle relaxants, and vitamin E had the highest associative increases in survival duration (p < 0.05). Random forests, which examined complex interactions, identified the following pharmaceuticals and supplements as most predictive to survival duration: Vitamin A, multivitamin, PEG supplements, alternative herbs, antihistamines, muscle relaxants, stimulant laxatives, and antispastics. Statins, metformin, and thiazide diuretics had insignificant associations with decreased survival.Keywords
Funding Information
- Alzheimer's Association (591014)
- National Institutes of Health (NS098228)
This publication has 68 references indexed in Scilit:
- Awareness of incurable cancer status and health-related quality of life among advanced cancer patients: A prospective cohort studyPalliative Medicine, 2011
- The Neurology Quality-of-Life Measurement InitiativeArchives of Physical Medicine and Rehabilitation, 2011
- Metformin Treatment Has No Beneficial Effect in a Dose-Response Survival Study in the SOD1G93A Mouse Model of ALS and Is Harmful in Female MicePLOS ONE, 2011
- Pain in Amyotrophic Lateral Sclerosis: A Neglected Aspect of DiseaseNeurology Research International, 2011
- Prognostic factors in ALS: A critical reviewAmyotrophic Lateral Sclerosis, 2009
- Quality of life in amyotrophic lateral sclerosis/motor neuron disease: A structured reviewAmyotrophic Lateral Sclerosis, 2009
- Morphine in the management of dyspnoea in ALS. A pilot studyEuropean Journal of Neurology, 2008
- The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse modelExperimental Neurology, 2008
- Psychological health in patients with amyotrophic lateral sclerosisAmyotrophic Lateral Sclerosis, 2007
- Evidence for the validity and reliability of the ALS assessment questionnaire: The ALSAQ-40Amyotrophic Lateral Sclerosis, 2000